Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)

NCT04551911 is registered in ClinicalTrials.gov with OPKO Health, Inc. as lead sponsor.

NCT NCT04551911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04551911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)
Lead sponsor
OPKO Health, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 2, 2020
Completion date
October 8, 2021
Enrollment
171 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus, covid-19, sars-cov2 infection